Vista Pharmaceuticals has signed a Non-Disclosure Agreement (NDA) with a company to acquire a complex ANDA for UROCARE. The US market size for this BRAND is $1.3 billion (Rs 8,840 crore) as per the latest IMS data. This ANDA will be manufactured at another USFDA approved Contract Manufacturing Facility (CMO) for 2 years.
The company already filed a complex ANDA in September 2017, targeting Cardialgy segment with a market size of $200 million (Rs 1,360 crore) as per latest IMS data. This product has a limited competition in the market and hence the company is expecting good revenues and profits from this product.
Vista Pharmaceuticals is engaged in manufacturing and selling of pharmaceutical, medical and veterinary preparations. The company also sells the products to its related companies, which are engaged in the manufacture of formulations.
